{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-065291","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-10-07T12:00:25+00:00","discovered_at":"2026-10-07T12:05:00.239410+00:00","generated_at":"2026-10-12T16:01:38.093148+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Spyre Therapeutics prices $350M stock offering at $85.00/share to fund SPY072 Phase 3 push in hidradenitis suppurativa","bullets":["Underwriting agreement dated October 5, 2026 with Jefferies, TD Securities, Leerink Partners and Stifel for 4,117,648 shares at $85.00/share, about $350.0M gross.","Underwriters granted a 30-day option on up to 617,647 additional shares; offering expected to close on or about October 7, 2026.","Proceeds fund Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness.","Part of the net proceeds will advance SPY072 into late-stage development for hidradenitis suppurativa, plus general infrastructure and potential in-licensing or acquisitions.","Offering made under shelf registration statement on Form S-3 (File No. 333-297063) effective June 26, 2026; final prospectus supplement dated October 5, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-065291","json":"https://secwatch.observer/filing/0001628280-26-065291.json","markdown":"https://secwatch.observer/filing/0001628280-26-065291.md","text":"https://secwatch.observer/filing/0001628280-26-065291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/0001628280-26-065291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026065291/syre-20261005.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:01:38.093148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}